Vincerx Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020
Market Capitalization	22	25	22	214	172
Market Cap Growth	390.38%	16.73%	-89.91%	24.86%	-
Enterprise Value	19	15	-27	107	110
PE Ratio	-	-0.63	-0.34	-5.45	-10.32
PB Ratio	-174.20	2.25	0.45	2.13	6.76
P/FCF Ratio	-3.09	-0.62	-0.36	-5.54	-75.28
P/OCF Ratio	-3.09	-0.62	-0.36	-6.41	-75.28
EV/EBITDA Ratio	-2.83	-0.38	0.44	-2.74	-6.60
EV/EBIT Ratio	-2.76	-0.37	0.44	-2.72	-6.60
EV/FCF Ratio	-3.00	-0.37	0.46	-2.76	-48.17
Debt / Equity Ratio	-3.57	0.22	0.07	0.04	-
Debt / EBITDA Ratio	-0.06	-0.06	-0.06	-0.11	-
Debt / FCF Ratio	-0.06	-0.06	-0.06	-0.11	-
Quick Ratio	0.70	2.67	5.89	8.02	1.63
Current Ratio	0.72	2.63	6.11	8.04	1.67
Return on Equity (ROE)	-303.10%	-187.70%	-93.00%	-52.70%	-164.60%
Return on Assets (ROA)	-168.40%	-126.30%	-77.90%	-39.70%	-25.30%
Return on Capital (ROIC)	-2190.86%	-310.47%	-139.31%	-59.96%	-42.22%
Earnings Yield	-175.70%	-159.17%	-291.41%	-18.35%	-9.69%
FCF Yield	-161.26%	-160.34%	-275.77%	-18.05%	-1.33%
Buyback Yield / Dilution	-1.00%	-1.26%	-22.43%	-227.04%	-320.16%
Total Shareholder Return	-1.00%	-1.26%	-22.43%	-227.04%	-320.16%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).